Umbilical cord blood stem cell transplantation (UCBT) is associated with retarded hematopoietic recovery and immune reconstitution and a high infection-related morbidity and mortality, especially after conditioning including anti-thymocyte globulin (ATG). However, data on immune recovery, incidence of infections, and outcome in double UCBT (dUCBT) recipients receiving an ATG-free reduced intensity conditioning (RIC) are lacking. In this study, recovery of lymphocyte subsets, thymopoiesis, and its association with severe infections and clinical outcome was assessed in a group of 55 recipients of a dUCBT ATG-free RIC regimen. T cell recovery was severely protracted in the majority of patients. However, T cell receptor excision circle TREC + T cells were detectable in 62% of patients at 3 months post-transplantation. A total of 128 common toxicity criteria grade 3−4 infections were observed in the first year post-transplantation. Non-relapse mortality at 12 months post-transplant was 16%, of which 78% infectious mortality. One-year overall survival was 73%. Patients who failed to recover thymopoiesis at 3 months post-transplantation were at a 3.3-fold higher risk of subsequent severe grade 3-4 infections.
Introduction
Umbilical cord blood (UCB) is an important alternative hematopoietic stem cell (HSC) source for patients needing an allogeneic stem cell transplantation (allo-SCT) who lack a suitable matched related or unrelated donor [1] . However, UCB transplantation (UCBT) is associated with retarded hematopoietic recovery and immune reconstitution, especially after conditioning including anti-thymocyte globulin (ATG), resulting in higher rates of infection compared to conventional HSC sources [2] [3] [4] . Especially, the relatively low number of progenitor cells present in the graft is associated with a higher rate of graft failure and retarded recovery [5] [6] [7] . Alternatively, two UCB grafts (double, dUCBT) instead of one were applied to increase the total nucleated cell and progenitor cell dose [8] [9] [10] . That approach appeared associated with less graft failure; however, hematopoietic recovery is still slow and results most time from one predominating unit [8, 11] .
Immune reconstitution upon allo-SCT is a complex process that consists of both the innate and the adaptive immune system. Recovery of innate immunity, characterized by restoration of mucosal barriers, neutrophil recovery, and natural killer (NK) cell recovery occurs within the first weeks post-transplant [12] . T cell reconstitution, which is part of the adaptive immune system, can take years to fully recover [13, 14] . T cell recovery after allo-SCT occurs via two independent routes. Initially, lymphopenia-induced homeostatic proliferation of mature T cells (either present in the graft or residual host T cells) results in the expansion of a T cell population with a limited T cell receptor (TCR) repertoire [4] . Long-term effective immune reconstitution with a broad T cell repertoire depends on thymic production of new naïve T cells (thymopoiesis) [15] . The presence of these newly formed naïve T cells can be detected by the measurement of signal joint TCR rearrangement excision DNA circles (sjTREC) that are formed during TCR rearrangement. Previously, we showed that retarded thymopoiesis strongly predicts for opportunistic infections in recipients of matched related and unrelated transplants [16] . Several studies showed higher rates of infectious morbidity and mortality upon single unit UCBT as compared to related or unrelated donor SCT, which appeared to be due to delayed functional T cell recovery [17] [18] [19] . Delayed immune recovery and a high incidence of infectious complications were observed in patients with high-risk hematological diseases after dUCBT preceded by either myeloablative (MA) or reduced intensity conditioning (RIC) [20] . However, it is still unclear to what extent impaired T cell recovery and thymopoiesis predicts for subsequent severe infections in dUCBT patients.
In the current study, hematopoietic recovery and immune recovery, including recovery of thymopoiesis, infections, and clinical outcome were evaluated in 55 poor-risk hematological patients receiving dUCBT upon conditioning using an ATG-free RIC regimen. Additionally, it was explored whether impaired recovery of thymopoiesis predicted for subsequent infections or was associated with infection-related mortality (IRM), non-relapse mortality (NRM), relapse-free survival (RFS) and overall survival (OS).
Methods

Patients and cord blood units
Patients receiving a dUCBT in the Erasmus MC Cancer Institute between September 2007 and December 2013 were included in this study. Patients were eligible for inclusion if they met the following criteria: (i) a diagnosis of a high-risk hematologic malignancy (as defined in [21] and further described in the Supplementary Information) in need for an allogeneic SCT but lacking a matched related or unrelated donor and therefore eligible for dUCBT; (ii) receiving an ATG-free RIC regimen; and (iii) presence of a peripheral blood sample to determine immune reconstitution and thymopoiesis available at 3 months post-transplantation. The institutional review board approved the protocols and all patients provided written informed consent. All patients were treated according to the HOVON 106 [11] and 115 study protocols (EudraCTnr.: 2008-000053-35 and 2012-001188-55/Netherlands Trial Registry: NTR1573 and NTR3535).
Cord blood unit selection, transplant procedures, and definitions are described in the Supplementary Information.
Infections
All infections diagnosed following transplantation between day +1 and day +365 post-transplant were evaluated and scored by grade, localization, and causative micro-organism according to the NCI common toxicity criteria (CTC) version 3.0, as described before [16, 22, 23] . Further details are described in the Supplementary Information.
Immune reconstitution analysis
Peripheral blood samples were acquired at baseline (after conditioning, but prior to dUCBT) and at 1, 2, 3, 6, and 12 months post-transplantation to determine post-transplant recovery of lymphocyte subsets, that is, CD3
+ , CD4 + , CD8 + , CD19
+ , and CD3 − CD16/56 + cells, using four-color single platform flow cytometry as described before [16] . In addition, the 3-month, 6-month, and 12-month samples were used to determine the frequency and absolute number of sjTREC + T cells. The quantification of signal joint TCR rearrangement excision circles is described in the Supplementary Information.
Statistical considerations
Endpoints of the study were neutrophil and platelet recovery, chimerism, acute graft-versus-host disease (aGVHD), chronic GVHD (cGVHD) 
Results
Patient characteristics
Fifty-five patients were included. Patients' characteristics are shown in Supplementary Table 1. The median age at inclusion was 51 years (range 23-68 years). Diagnoses included acute leukemia (53%), chronic leukemia (9%), lymphoma (11%), and myelodysplastic syndromes, myeloproliferative diseases, or bone marrow failure (27%). Seventeen percent of the patients had a high (6 or 7) European Group for Blood and Marrow Transplantation (EBMT) risk score, while 34% of patients were at higher risk for NRM according to the hematopoietic cell transplantation-co-morbidity index (HCT-CI). The majority of patients received either two 4/6 matched units (36%) or one 4/6 matched unit combined with a 5/6 matched unit (42%).
Engraftment and chimerism
Fifty-two patients (95%) met the criteria for engraftment with a median time to neutrophil recovery of 34 days ( Fig. 1 , range 12-57 days). Of the patients who did not meet the criteria for engraftment, one suffered from primary graft failure and two from relapse. Platelet recovery (≥50 × 10 9 / L) occurred at a median of 45 days (Fig. 1 , range 23-139 days). Three patients did not achieve neutrophil recovery (5%), while four patients did not achieve platelet recovery (7%). At 3 months post-transplantation complete donor chimerism in the bone marrow, either single or double donor derived, was observed in 49/55 patients (Table 1, 89%). Mixed chimerism was observed in four patients (7%), while two patients (4%) still showed full recipient chimerism. One of these patients suffered from relapse, and the other from primary graft failure.
Immune reconstitution
Lymphocyte recovery was assessed at baseline and at 1, 2, 3, 6, 12, and 24 months post-transplantation. 
Infections
The total number of infections was recorded in detail in surviving patients up to 1 year after dUCBT, resulting in a total of 197 CTC grade 2-4 and 128 CTC grade 3-4 infections (details in Supplementary Table 2 ). The cumulative incidence of CTC grade 2-4 and grade 3-4 infections, respectively, was 81% and 80% at 3 months and 95% and 87% at 12 months. In the first 30 days post-transplantation, the rate of infections was 3.16 CTC grade 3-4 infections per 100 patient-days ( 
Outcome
Median follow-up was 20 months. At 1 year post-transplantation, 40 of 55 patients (73%) were still alive (Fig. 4a) . The EBMT risk score significantly impacted on OS (Fig. 4b, HR 2 .36, 95% CI: 1.35-4.12, p = 0.003). The HCT-CI score was also associated with OS (HR 1.51, 95% CI: 0.96-2.39); however, this did not reach statistical significance (p = 0.076). Fifteen patients had died within the first year after transplantation. Death was due to relapse in six patients (40%), allo-SCT-related causes in seven patients (47%), and other causes in two patients (13%; peritonitis of unknown cause and death of unknown cause, respectively). In the seven patients who died from allo-SCT-related causes, infectious complications contributed in all patients and were the primary cause of death in six out of seven patients. In four patients, the infection co-occurred with GVHD. By day 100 post-transplant, 28 patients (51%) had developed grade II-IV aGVHD, and 4 patients (7%) developed grade III-IV aGVHD. Limited or extensive cGVHD was observed in 9 and 15 out of 55 patients (16% and 27%, respectively) at 1 year post-transplant. Preceding aGVHD was associated with IRM and OS beyond 3 months post-transplantation; however, this did not reach statistical significance (IRM: HR 7.5, 95% CI: 0.92-61.19, p = 0.06; OS: HR 2.18, 95% CI: 0.99-4.81, p = 0.055). Unfortunately, given the small number of patients who had severe GVHD (n = 4), subgroup analyses would lack power.
Impact of the recovery of thymopoiesis on outcome
Next, it was explored whether recovery of sjTREC + T cells at 3 months post-transplantation was associated with severe infections (CTC grade 3-4), IRM, NRM, RFS, and OS determined from 3 months post-transplantation. In univariate analysis (Table 3) 
Discussion
Immune reconstitution upon UCBT is severely retarded, especially after conditioning including ATG, and as a direct consequence, UCBT is associated with a significant risk of opportunistic infections [24] . Kinetics of immune reconstitution upon UCBT have been widely studied, although most of these studies were performed in a single graft setting and are based on mixed populations of patients, receiving various conditioning and immunosuppressive regimens [15, [17] [18] [19] [25] [26] [27] . Few studies reported on recovery of thymopoiesis upon dUCBT preceded by either MA or RIC regimens including ATG [20, 28, 29] . Our study is the first study to correlate immune reconstitution including thymic recovery with the occurrence of subsequent severe viral, bacterial, and fungal infections in a group of dUCBT patients who have received an ATG-free RIC regimen. Our study shows the predictive impact of impaired sjTREC + T cell recovery at 3 months on the risk of severe infections beyond that time point, suggesting that the new T cells generated are pivotal for adequate antiinfectious immunity. Although CD3 + T cell recovery was severely protracted and the majority of patients had CD3 + T cell levels below the normal range up to 24 months post-transplantation, sjTREC + T cells were detected at low levels in 62% of patients at 3 months post-transplantation. Our results are in contrast to several other studies, in which sjTREC + T cells were detected in 20% [20] , 11% [29] , and 0% [30] of patients around the same time point upon dUCBT. However, in these studies, patients received either MA conditioning or a RIC regimen combined with ATG, resulting in profound in vivo T cell depletion [31] . Cytotoxic chemotherapy and radiation negatively affect thymic reconstitution [32, 33] . RIC regimens may therefore cause less damage to the thymus compared to MA conditioning, resulting in faster recovery of thymopoiesis. In addition, several studies showed an association between the use of a RIC regimen and enhanced immune reconstitution [34] [35] [36] . The use of ATG results in a lower incidence of GVHD, but, however, might result in delayed immune reconstitution as well. Enhanced B and T cell recovery is reported upon the use of ATG-free conditioning regimens in UCBT, both MA or RIC, in both pediatric and adult cohorts [37] [38] [39] . In addition, ATG in combination with conditioning strongly impairs thymic recovery of CD4 + T cells [40] . Therefore, the high incidence of patients with detectable sjTREC + T cells at 3 months post-transplantation could be well explained by the relatively mild conditioning regimen used in our study. In a comparable cohort of 46 adult patients receiving a matched related (n = 33) or unrelated (n = 13) allo-SCT upon an ATG-free RIC regimen (fludarabine 90 mg/m 2 and total body irradiation 2 Gy) in our center, detectable sjTREC + T cells were observed in 67% of patients at 3 months and 86% at 12 months, which is similar to the above-described proportions of sjTREC + T cell positivity in patients receiving dUCBT. These results indicate that upon an ATG-free RIC regimen, dUCBT and adult donor allo-SCT show comparable reconstitution of thymopoiesis. Previously, both age and GVHD have been HCT-CI hematopoietic cell transplantation-co-morbidity index, aGVHD acute graft-versus-host disease implicated to impact the reconstitution of thymopoiesis [36, [40] [41] [42] , and also here higher age appeared associated with undetectable sjTREC + T cells.
The significant prognostic value of early thymopoiesis for subsequent infections after dUCBT highlight the need to improve thymic function post-transplantation. New approaches to boost thymopoiesis include the exogenous administration of cytokines, such as IL-7, FMS-like tyrosine kinase 3 ligand, keratinocyte growth factor, and IL-22, that may directly exert a stimulatory effect on the development of thymocytes or promote the survival and/or proliferation of thymic epithelial cells, thereby indirectly stimulating thymopoiesis [43] [44] [45] [46] [47] . Apart from cytokine-based approaches also regenerative cellular strategies to boost thymopoiesis receive increased attention. Thymic epithelial progenitor cells have been successfully generated ex vivo by directed differentiation of human embryonic stem cells (hESC). These de novo generated hESC-derived thymic epithelial cells further mature into functional thymic epithelial cells that support T cell development upon transplantation into thymus-deficient mice [48, 49] . Impaired thymopoiesis post UCBT may not only result from thymic disfunction but also from the low number of T cell progenitors present in the UCB graft that enter into the thymus. Approaches to ex vivo generate human progenitor T cells from UCB-derived hematopoietic stem/progenitor cell, using a OP9-DL1 co-culture system, that may increase the number of thymus-seeding progenitors and thereby thymopoiesis are pursued [46] . Which of these approaches reach clinical safety and functional efficacy remains to be established.
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